These findings suggest that PDLIM1 acts as a downstream effector of ACTN2, regulating VSMC proliferation, apoptosis, and inflammation, and plays a critical role in aneurysm progression, highlighting its potential as a therapeutic target. Here, ACTN2 is linked to aneurysm.